• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性乳腺癌和原发性卵巢癌患者的临床特征及生存结局

Clinical characteristics and survival outcomes of patients with both primary breast cancer and primary ovarian cancer.

作者信息

Chen Chang, Xu Yali, Huang Xin, Mao Feng, Shen Songjie, Xu Ying, Sun Qiang

机构信息

Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Medicine (Baltimore). 2020 Aug 7;99(32):e21560. doi: 10.1097/MD.0000000000021560.

DOI:10.1097/MD.0000000000021560
PMID:32769897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7593036/
Abstract

Breast cancer and ovarian cancer are closely related. The major common risk factors of these 2 types of cancer are likely genetic factors. However, few studies have shown any common characteristics in patients who have both types of these 2 cancers. The purpose of this retrospective study is to explore the clinical characteristics and survival outcomes of patients with both primary breast cancer and primary ovarian cancer.A cohort of patients who had a history of both primary breast cancer and primary ovarian cancer were enrolled, and they received treatment in the Peking Union Medical College Hospital between January 1, 2010, and December 31, 2018. Both descriptive statistics analysis and survival analysis were performed for analysis.A total of 114 patients with both primary breast cancer and primary ovarian cancer were included in the study. The median (range) follow-up was 129.5 (20-492) months. The average interval time between the diagnosis of 2 types of cancer was 79.4 months in patients having ovarian cancer firstly and was 115.9 months in patients having breast cancer firstly. The 5- and 10-year overall survival (OS) rates were 91.5% and 81.7% for patients with ovarian cancer following breast cancer, respectively, and 90.6% and 87.5% for patients with breast cancer following ovarian cancer, respectively. Multivariate analysis revealed that independent predictors of OS were the age of diagnosis of the first tumor and the time interval between two types of tumor in patients with ovarian cancer following breast cancer.Most breast cancer or ovarian cancer occurred within 5 years after being diagnosed with the first tumor, and the interval time was significantly shorter in patients with previous ovarian cancer. The prognosis is likely positively correlated to the interval time between the occurrences of two types of cancer.

摘要

乳腺癌和卵巢癌密切相关。这两种癌症的主要共同风险因素可能是遗传因素。然而,很少有研究表明同时患有这两种癌症的患者有任何共同特征。这项回顾性研究的目的是探讨原发性乳腺癌和原发性卵巢癌患者的临床特征和生存结果。

纳入了一组有原发性乳腺癌和原发性卵巢癌病史的患者,他们于2010年1月1日至2018年12月31日在北京协和医院接受治疗。进行描述性统计分析和生存分析。

该研究共纳入114例原发性乳腺癌和原发性卵巢癌患者。中位(范围)随访时间为129.5(20 - 492)个月。首先诊断为卵巢癌的患者,两种癌症诊断之间的平均间隔时间为79.4个月;首先诊断为乳腺癌的患者,平均间隔时间为115.9个月。乳腺癌后发生卵巢癌的患者,5年和10年总生存率(OS)分别为91.5%和81.7%;卵巢癌后发生乳腺癌的患者,5年和10年总生存率分别为90.6%和87.5%。多因素分析显示,乳腺癌后发生卵巢癌的患者中,总生存的独立预测因素是首次肿瘤诊断时的年龄和两种肿瘤之间的时间间隔。

大多数乳腺癌或卵巢癌发生在首次肿瘤诊断后的5年内,既往有卵巢癌的患者间隔时间明显更短。预后可能与两种癌症发生之间的间隔时间呈正相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/50ea93d54514/medi-99-e21560-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/dc570f17ecb6/medi-99-e21560-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/51ed2bf700b6/medi-99-e21560-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/d46fbbca4706/medi-99-e21560-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/53ef2004547d/medi-99-e21560-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/1a525e9f7fb2/medi-99-e21560-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/50ea93d54514/medi-99-e21560-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/dc570f17ecb6/medi-99-e21560-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/51ed2bf700b6/medi-99-e21560-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/d46fbbca4706/medi-99-e21560-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/53ef2004547d/medi-99-e21560-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/1a525e9f7fb2/medi-99-e21560-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/7593036/50ea93d54514/medi-99-e21560-g011.jpg

相似文献

1
Clinical characteristics and survival outcomes of patients with both primary breast cancer and primary ovarian cancer.原发性乳腺癌和原发性卵巢癌患者的临床特征及生存结局
Medicine (Baltimore). 2020 Aug 7;99(32):e21560. doi: 10.1097/MD.0000000000021560.
2
Survival Outcomes of Patients with Primary Breast Cancer Following Primary Ovarian Cancer.原发性乳腺癌患者继原发性卵巢癌后的生存结局。
Med Sci Monit. 2019 May 24;25:3869-3879. doi: 10.12659/MSM.914163.
3
[Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].同步原发性子宫内膜癌和卵巢癌的临床病理及生存分析
Zhonghua Fu Chan Ke Za Zhi. 2018 Dec 25;53(12):816-822. doi: 10.3760/cma.j.issn.0529-567x.2018.12.004.
4
Clinicopathologic and survival analyses of synchronous primary endometrial and epithelial ovarian cancers.同步原发性子宫内膜癌和上皮性卵巢癌的临床病理及生存分析
J Obstet Gynaecol Res. 2015 Nov;41(11):1813-9. doi: 10.1111/jog.12826. Epub 2015 Sep 14.
5
Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.
Cancer. 1992 Oct 15;70(8):2129-36. doi: 10.1002/1097-0142(19921015)70:8<2129::aid-cncr2820700820>3.0.co;2-u.
6
[Clinical analysis of 91 cases of hereditary breast and ovarian cancer].91例遗传性乳腺癌和卵巢癌的临床分析
Zhonghua Zhong Liu Za Zhi. 2005 Apr;27(4):245-7.
7
Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis.乳房切除术后乳腺癌的局部区域复发:总是致命事件吗?单因素和多因素分析结果
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):853-63. doi: 10.1016/s0360-3016(96)00556-1.
8
Recurrence season impacts the survival of epithelial ovarian cancer patients.复发季节影响上皮性卵巢癌患者的生存。
Asian Pac J Cancer Prev. 2014;15(4):1627-32. doi: 10.7314/apjcp.2014.15.4.1627.
9
Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?复发性上皮性卵巢癌二次细胞减灭术后复发部位是否影响生存?
J Obstet Gynaecol. 2020 Aug;40(6):849-855. doi: 10.1080/01443615.2019.1674264. Epub 2020 Jan 14.
10
Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.卵巢癌患者骨髓中播散肿瘤细胞的预后相关性的荟萃分析。
Int J Gynecol Cancer. 2013 Jun;23(5):839-45. doi: 10.1097/IGC.0b013e3182907109.

引用本文的文献

1
Breast and Ovarian Cancers' Incidence Trends Among Iraqi Women During 2012-2022 and Their Relationship to Fertility Patterns.2012 - 2022年伊拉克女性乳腺癌和卵巢癌的发病趋势及其与生育模式的关系
Sultan Qaboos Univ Med J. 2025 May 2;25(1):499-505. doi: 10.18295/2075-0528.2863. eCollection 2025.
2
Microfluidics engineering towards personalized oncology-a review.面向个性化肿瘤学的微流控工程——综述
In Vitro Model. 2023 Jul 13;2(3-4):69-81. doi: 10.1007/s44164-023-00054-z. eCollection 2023 Aug.
3
PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer.

本文引用的文献

1
Breast cancer statistics, 2019.乳腺癌统计数据,2019 年。
CA Cancer J Clin. 2019 Nov;69(6):438-451. doi: 10.3322/caac.21583. Epub 2019 Oct 2.
2
Survival Outcomes of Patients with Primary Breast Cancer Following Primary Ovarian Cancer.原发性乳腺癌患者继原发性卵巢癌后的生存结局。
Med Sci Monit. 2019 May 24;25:3869-3879. doi: 10.12659/MSM.914163.
3
Cancer statistics, 2019.癌症统计数据,2019 年。
PARP 抑制剂在有 BRCA1/2 种系突变和乳腺癌病史的卵巢癌患者中的反应和结局。
J Gynecol Oncol. 2024 Jul;35(4):e51. doi: 10.3802/jgo.2024.35.e51. Epub 2024 Jan 12.
4
A cost-utility analysis of and testing in high-risk breast cancer patients and family members in Thailand: a cost-effective policy in resource-limited settings.在泰国高危乳腺癌患者及其家属中进行和检测的成本效用分析:资源有限环境下具有成本效益的政策。
Front Public Health. 2023 Dec 14;11:1257668. doi: 10.3389/fpubh.2023.1257668. eCollection 2023.
5
A Multilabel Text Classifier of Cancer Literature at the Publication Level: Methods Study of Medical Text Classification.出版物层面癌症文献的多标签文本分类器:医学文本分类方法研究
JMIR Med Inform. 2023 Oct 5;11:e44892. doi: 10.2196/44892.
6
Common Multiple Primary Cancers Associated With Breast and Gynecologic Cancers and Their Risk Factors, Pathogenesis, Treatment and Prognosis: A Review.与乳腺癌和妇科癌症相关的常见多发性原发性癌症及其危险因素、发病机制、治疗和预后:综述
Front Oncol. 2022 Jun 8;12:840431. doi: 10.3389/fonc.2022.840431. eCollection 2022.
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
4
Surgical prevention strategies in ovarian cancer.卵巢癌的手术预防策略。
Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4.
5
Comparisons of gene coexpression network modules in breast cancer and ovarian cancer.乳腺癌和卵巢癌中基因共表达网络模块的比较。
BMC Syst Biol. 2018 Apr 11;12(Suppl 1):8. doi: 10.1186/s12918-018-0530-9.
6
Real-world evidence in the treatment of ovarian cancer.卵巢癌治疗的真实世界证据。
Ann Oncol. 2017 Nov 1;28(suppl_8):viii61-viii65. doi: 10.1093/annonc/mdx443.
7
Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.研究卵巢癌亚型流行病学中的挑战与机遇
Curr Epidemiol Rep. 2017 Sep;4(3):211-220. doi: 10.1007/s40471-017-0115-y. Epub 2017 Jul 10.
8
Managing hereditary breast cancer risk in women with and without ovarian cancer.管理有和无卵巢癌的女性的遗传性乳腺癌风险。
Gynecol Oncol. 2017 Jul;146(1):205-214. doi: 10.1016/j.ygyno.2017.04.013. Epub 2017 Apr 25.
9
Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?BRCA 突变携带者诊断为卵巢癌后患乳腺癌的风险:预防性乳房切除术是否必要?
Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.
10
Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence.中国乳腺癌的描述性流行病学:发病率、死亡率、生存率和患病率。
Breast Cancer Res Treat. 2016 Oct;159(3):395-406. doi: 10.1007/s10549-016-3947-0. Epub 2016 Aug 25.